Cancer Vaccines: Breakthroughs, Challenges, and Future Perspectives in Oncology

Cancer continues to pose a significant global health burden, accounting for millions of cases and fatalities each year. Conventional therapeutic modalities, including surgery, chemotherapy, and radiotherapy, have yielded improved outcomes. However, their limitations and adverse effects underscore the imperative for novel therapeutic strategies, such as cancer vaccines. These vaccines, grounded in immunotherapeutic principles, have been shown to activate the immune system, thereby inducing tumor-specific responses. This mini-review explores the immunological foundations, classifications, and current limitations of cancer vaccines, with emphasis on peptide-based, recombinant, cell-based, and nucleic acid-based modalities. The manuscript also examines the significance of neoantigen identification and the tumor microenvironment in determining vaccine effectiveness. Notwithstanding noteworthy advancements, challenges such as immune evasion, low mutation rates, and an immunosuppressive tumor milieu endure. The effective incorporation of cancer vaccines into standard oncological care is contingent upon future research and clinical breakthroughs.